Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dirk Thye
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Beta
- 1.31
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.15
Financials
Net Income
$-75.49MEBITDA
$-75.41MFree Cash Flow
$-18.89MEPS (diluted)
$-12.31Shares Outstanding (diluted)
6.13M+5591.4%Operating Expenses
$22.09MCash & Debt
$115.98MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-83.98M | $-336.00 |
| 2024 | $0.00 | $-56.83M | $-262.00 |
| 2023 | $0.00 | $-31.39M | $-168.00 |
| 2022 | $0.00 | $-51.66M | $-308.00 |
| 2021 | $0.00 | $-89.94M | $-606.00 |
| 2020 | $0.00 | $-76.85M | $-526.00 |
| 2019 | $0.00 | $-36.98M | $-386.00 |
| 2018 | $0.00 | $-12.48M | $-116.00 |
| 2017 | $0.00 | $-12.23M | $-114.00 |
Valuation
QNCXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·7d ago·Positive
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Quince Therapeutics to Participate in September 2026 Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026:
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-1.49 per share
Typical surprise -21.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-12.31 vs $-28.02beat
- Tue, May 12$75.60 vs $-26.00beat
- Mon, Apr 6$-3.50 vs $-3.59beat
- Wed, Nov 12$-50.00 vs $-40.00miss
- Mon, Aug 11$-68.00 vs $-56.00miss
- Tue, May 13$-68.00 vs $-48.00miss
Estimates and results for QNCX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by QNCX officers and directors.
- Bought
- $1.1m
- Sold
- $174k
28 trades
1 trade
- Benatti Lucasold
- Thye Dirkbought
- Thye Dirkbought
- Hannah Brendanbought
- Hannah Brendanbought
- Hannah Brendanbought
- Ryan Charles S.bought
- Hannah Brendanbought
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in QNCX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.